Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea

Key Inclusion Criteria: * Individuals aged 12 years and older who are living in Korea * Individuals with chronic HCV infection eligible for treatment with Sovaldi as indicated in the approved prescribing information for Sovaldi * Individuals who have been informed of all pertinent aspects of the study and have voluntarily signed Personal Information Protection Act (PIPA) consent form; Pediatric individuals who have their legally authorized representatives sign the PIPA consent form Key Exclusion Criteria: * Individuals treated with Sovaldi outside of the approved prescribing information for Sovaldi in Korea * Individuals who have a contra-indication (refer to the Korea prescribing information) * Individuals who have a contra-indication to ribavirin or peginterferon alfa or daclatasvir * Pregnant or breast feeding women * Individuals who have previously been administered Sovaldi * Individuals participating in a concurrent HCV clinical trial * Individuals planning on leaving the country during the study period Note: Other protocol defined Inclusion/Exclusion criteria may apply.